SUMMARY Protein electrophoresis was carried out on 102 000 samples from the patients of a district general hospital over 10 years, and a monoclonal protein was detected in 730 cases; of these, 114 could be classified as B cell malignancies and 261 as monoclonal gammopathy of undefined significance (MGUS). The various clinical and laboratory features of monoclonal gammopathy were examined with respect to distinguishing the malignant conditions from MGUS at first presentation.
Monoclonal immunoglobulin is the product of an expanded clone of B cells and is characteristically detected as a discrete band, or paraprotein, by electrophoresis of the serum or urine. The clone of cells producing the paraprotein can result from either a benign or malignant proliferation of B lymphocytes.
The patient whose monoclonal immunoglobulin is associated with overt B cell malignancy can usually be identified by a combination of clinical and laboratory findings. In the diagnosis of benign paraproteinaemia a temporal stability is implicit. In the time before follow up data become available the presence of a monoclonal protein in the absence of associated pathology has been defined as monoclonal gammopathy of undefined significance (MGUS).1
The humoral characteristics of MGUS are represented by a low concentration of monoclonal protein,23 undetectable Bence-Jones protein,2 normal bone marrow plasma cell morphology at less than 10%4 and normal concentrations of albumin,4 haemoglobin,5 and polyclonal immunoglobulin. 4 Screening of general populations or blood donors shows that benign paraproteinaemia predominates, suggesting that only a small proportion of cases progress to frank malignancy. In hospital patients who represent a more selected population a higher incidence of malignancy is associated with the chance finding of a paraprotein.6 As the laboratory inAccepted for publication 3 Feburary 1987 vestigation of many hospital patients may include serum and urine electrophoresis, chance findings of monoclonal immunoglobulins in this group is clearly clinically important.
In the present study samples from a large hospital population were screened by electrophoresis and, whenever possible, patients with a monoclonal immunoglobulin were classified as having B Table 2 shows the distribution in MGUS.
A suppression of polyclonal immunoglobulin concentration that is, one or more non-paraprotein immunoglobulin values below the lower limit of the reference range, was seen in 11 8% of patients with MGUS and 96% of those with myeloma. In MGUS this suppression was not related to organ disease but rather to age (table 3). The incidence increased with age, and the overall incidence was greater in men (154:107). Over the age of 75 years the male:female ratio of the patients with MGUS was I 0, but in the population as a whole in this age group, women outnumber men by 2-5:1. Therefore, when the incidence Malacrida, de Francesco, Banfi, Porta, Riches (19-2%), bladder (15-5%), stomach (13-4%) with minor occurrences of other tumours. The most common non-malignant disease was of cardiovascular origin (18-4%). Other conditions were mainly inflammatory (infection, arthropathy, autoimmune) or chronic.
Where possible, patients in the MGUS group had investigations repeated at least yearly. Only five patients progressed to frank malignancy, at times varying from 1 (P1) to 10 years (P5) after presentation. The figure shows the paraprotein concentrations in these five patients.
Follow up studies in a further 92 patients, initially diagnosed as having MGUS, indicated no progression to B cell malignancy during the time of the study; 75 for one to seven years, 13 for nine years, and three for 10 years. All 22 patients in whom BenceJones protein was detected were included in this group, as were 25 patients who had paraprotein concentrations between 20-30 g/l at presentation: table 4 shows the number of years for which follow up data were available for patients in these two groups. Of the four patients with paraprotein concentrations greater than 30 g/l, one showed a 21% decrease after two years, and in the other three followed up for five, eight, and 10 years, respectively, the paraprotein concentration remained stable.
Of the total group of 92 patients with MGUS, 62 patients showed some variation in paraprotein concentration during the time of the study. The paraprotein was found to decrease in 17 cases, to be transient in four, and to increase in 41, although these increases were neither progressive nor was there any other suggestion of evolution to B cell malignancy. The mean survival of the paraprotein in patients with transient MGUS was three months. There was no consistent pattern of associated disease in those patients who did not progress to B cell malignancy but who did show some variation in paraprotein concentrations (table 5) .
Discussion
In agreement with many other workers an absolute 795 The number of patients with MGUS and immune suppression shown in the present series (11-8%) is somewhat lower than those previously published.
Increased numbers of plasma cells were seen in the bone marrow biopsy specimen of a number of patients with MGUS, but with no aberrant morphology. The finding of abnormal plasma cells is therefore a more important feature than absolute numbers, as was stated many years ago. '7 MGUS prevailed in elderly patients and was more common in men than women when the incidence was adjusted according to population statistics.
In this study 6% of patients with MGUS were asymptomatic, which agrees with the 5-10% reported by Isobe. 8 In other series the reported incidence has been much higher at 26%' and 37%,19 which may simply reflect variations in patient populations.
The association of MGUS with neoplasia is a common finding' 16 18 2021 as with inflammatory conditions.'8 This was also found in this series in which 20% of MGUS were associated with non-B cell neoplasia. The distribution of the different neoplasms was as expected from the reported prevalence in the general population in this region. 22 The prevalence of the different types of tumours associated with MGUS was variable'182 23 but may have reflected the variation in populations.
As might be expected, most of the transient paraproteins in the present series were associated with acute viral or bacterial infections, more unusual was the finding in one patient with coeliac disease. An association of transient paraproteinaemia with coeliac disease has been noted previously. 24 An important criterion of benign paraproteinaemia is that the paraprotein concentration should remain stable. In several patients with MGUS there was some increase in concentration, and these patients may have represented a group in the early stage of development of benign paraproteinaemia in which the B cell clone was still expanding before becoming stabalised.
The progression from apparent MGUS to frank malignancy in 5 4% of cases compares with the low rates previously reported,' 25 although a much higher rate of 19% has also been reported'9; but again this variation may reflect differences in patient selection or population.
In conclusion, most of the laboratory investigations used to assess the clinical importance of paraproteinaemia either alone or in combinations are unable to distinguish absolutely malignant conditions from MGUS, and it remains important to do follow up studies with regular reassessment of laboratory and clinical findings.
